Aigen Investment Management LP Has $370,000 Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Aigen Investment Management LP lifted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 41.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,943 shares of the biopharmaceutical company’s stock after buying an additional 8,456 shares during the quarter. Aigen Investment Management LP’s holdings in Dynavax Technologies were worth $370,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Nisa Investment Advisors LLC increased its position in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the period. Sanctuary Advisors LLC grew its position in shares of Dynavax Technologies by 6.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 1,109 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares in the last quarter. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,034 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Up 0.4 %

NASDAQ DVAX opened at $14.40 on Friday. The business has a fifty day moving average price of $13.01 and a two-hundred day moving average price of $12.21. The stock has a market capitalization of $1.79 billion, a PE ratio of 80.00 and a beta of 1.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Equities analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price target for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.